Immunosuppression in uveitis.

摘要

The treatment of ocular inflammatory disease continues to be a major challenge as the clinician tries to balance the risks and the benefits of immunosuppressive therapy. Currently, corticosteroids, antimetabolites, and calcineurin inhibitors are the most commonly used agents. Biologically active agents including monoclonal antibodies, however, provide a promising new form of treatment that can target the immune system more specifically and more safely. Long-term studies are needed to determine the role of biologic agents in the treatment of uveitis.